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SAFETY AND EFFICACY OF 
APROTININ UNDER 
CONDITIONS OF DEEP 
HYPOTHERMIA AND 
CIRCULATORY ARREST 
Aprotinin has been successfully used to reduce blood loss and blood 
product requirements in patients undergoing primary and reoperative 
cardiac operations. Its safety and efficacy during profound hypothermia 
and circulatory arrest have been questioned, however. A retrospective 
review compared 24 patients who received aprotinin during complex aortic 
procedures under profound hypothermia and circulatory arrest with 24 
age-matched patients undergoing similar procedures without aprotinin. 
Activated clotting time was maintained at longer than 500 seconds (kaolin 
activating agent) or longer than 750 seconds (celite). We observed no 
statistically significant difference in the incidence of ueurologic events (p 
not significant) or myocardial infarctions (p not significant), and there was 
a trend toward reduced in-hospital mortality rate in aprotiuin-treated 
patients. A higher incidence of postoperative renal dysfunction was encoun- 
tered in apr0tinin-treated patients. Aprotinin recipients had a significant 
reduction in requirements for postoperative homologous erythrocytes (p = 
0.01). We conclude that aprotinin may be safely and effectively used in 
patients undergoing deep hypothermia and circulatory arrest. (J THol~c 
CARDIOVASC SURG 1995;110:1615-22) 
Daniel J. Goldstein, MD, Carolyn M. DeRosa, BA, Linda B. Mongero, CCP, 
Alan D. Weinberg, MS, Robert E. Michler, MD, Eric A. Rose, MD, 
Mehmet C. Oz, MD, and Craig R. Smith, MD, New York, N.Y. 
A Protinin (Trasylol), a bovine-derived nonspecific protease inhibitor, has been successfully used to 
decrease blood loss and blood product requirements 
in patients undergoing primary 1'2 and reopera- 
tive 3, 4 cardiac operations. Its mechanism of action 
has not yet been fully elucidated, but it is thought o 
reduce fibrinolysis, '6 inhibit neutrophil activation, 7 
and preserve platelet function, s' 9 
Patients undergoing complex aortic procedures 
performed with deep hypothermia nd total circu- 
latory arrest face a significant bleeding risk and 
would therefore be expected to benefit from the use 
of aprotinin. Two recent series reported an in- 
creased incidence of death, renal dysfunction, and 
multiorgan platelet thrombi in aprotinin recipients 
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undergoing such procedures, m' n An initial review 
of our experience did not support these findings. ~2 
To address these issues, we completed a review of 
our institutional experience of complex aortic pro- 
cedures performed with deep hypothermia (18 ° C), 
circulatory arrest, and the use of aprotinin. 
Methods 
Between November 1, 1991, and June 31, 1994, 23 
patients underwent complex aortic procedures and one 
patient underwent a renal tumorectomy under deep hy- 
pothermia nd circulatory arrest with intraoperative use 
of aprotinin. Before this time, aprotinin was not used at 
our institution for this purpose. Twenty-four patients 
undergoing similar procedures without aprotinin during a 
more extended period (May 1, 1987, to December 31, 
1993) were matched for age and type of operation to form 
a control group. The clinical, anesthesia, nd perfusion 
records of all 48 patients were reviewed. Signed consent 
for aprotinin use was obtained for all treated patients 
under a protocol reviewed by the Institutional Review 
Board. 
The treated group received the conventional "Ham- 
mersmith" (full dose) aprotinin regimen: (1) to assess the 
potential for an allergic reaction, a test dose of 1.4 mg 
(10,000 kIU) was given intravenously; (2) after induction 
of anesthesia but before sternotomy, a loading dose 
consisting of 280 mg (2,000,000 klU) was administered; 
(3) a pump prime dose of 280 mg was added to the 
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Table I. Clinical profile of aprotinin-treated and untreated (control) patients 
Aprotinin No aprotinin 
Number of cases 24 24 
Age (yr) 
Mean + SD 61.9 + 14 62.8 +_ 12 
Range 42-84 31-80 
Sex (M/F) 13/10" 16/8 
History 
Previous ternotomy 16.7% (4/24) 4.2% (1/24) 
Diabetes mellitus 0% (0/24) 4.3% (1/23)~ 
Hypertension 58.3% (14/24) 59% (13/22)§ 
Preoperative r nal insufficiency? 34.7% (8/24) 45.8% (11/24) 
Principal diagnosis 
Acute aortic dissection 19 20 
Thoracic aortic aneurysm 3 3 
Innominate stenosis 1 0 
Renal tumor with inferior vena 1 1 
cava invasion 
Secondary diagnosis 
Aortic regurgitation 6 7 
Coronary artery disease 4 1 
Mitral regurgitation 0 1 
Primary surgical procedures 
Repair of aortic dissection 19 20 
Replacement of aorta 3 3 
Aorta-innominate artery bypass 1 0 
Renal tumorectomy 1 1 
Secondary surgical procedures 
Resuspension of aortic valve 9 9 
Aortic valve replacement 2 3 
Coronary artery bypass grafting 4 1 
Reimplantation ofcoronary artery 3 1 
Mitral valve replacement 0 1 
*One patient underwent two operations. 
?Serum creatinine l vel greater than 1.5 mg/dl. 
SData not available for one patient. 
§Data not available for two patients. 
cardiopulmonary b pass (CPB) circuit before institution 
of CPB; and (4) the loading dose was followed by a 
constant infusion of 70 mg/hr (250,000 kIU/hr) until 
conclusion of the operation. Aprotinin and all other 
intravenous infusions were stopped during circulatory 
arrest and restarted after resumption of CPB. One patient 
in the treated group exposed to aprotinin during a previ- 
ous operation was skin tested for aprotinin hypersensitiv- 
ity, with negative results. 
Initial anticoagulation consisted of 300 units/kg of in- 
travenous heparin, with 4000 units added to the pump 
prime. Activated clotting time (ACT) was measured at the 
following points: (1) before CPB, (2) every 20 minutes 
during CPB, (3) immediately before circulatory arrest, (4) 
on restoration of CPB, and (5) 10 minutes after protamine 
reversal. ACT was maintained at longer than 750 seconds 
(with celite activating agent) or longer than 500 seconds 
(with kaolin). Protamine dosage was determined by hep- 
arin-protamine titration assay and by measurement of 
heparin levels (Hepcon HMS; Medtronic Hemotech, 
Englewood, Colo.). 
Results 
Patient characteristics, Table I summarizes im- 
portant  demographic  and clinical characteristics 
of both groups. The control  group consisted of 24 
patients with a mean (+ standard deviation [SD]) 
age of 62.8 _ 12 years. The aprot inin group 
comprised 23 patients, with one patient undergo-  
ing two aortic dissection repair procedures 105 
days apart, for a total of  24 procedures.  Mean age 
in the aprot inin group was 61.9 _+ 14 years. The 
incidences of diabetes and hypertension were 
comparable  in both groups, whereas the control  
group had a higher incidence of preoperat ive 
renal dysfunction (serum creatinine level >1.5 
mg/dl). Four  patients in the aprotinin group and 
one patient'  in the control  group had undergone 
previous sternotomy. One patient in each group 
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Table II. Intraoperative time variables for aprotinin-treated and untreated (control) patients" 
P 
Aprotinin No aprotinin Value 
CPB time (rain) 
Mean + SD 183.] _+ 65 154.7 + 49 0.01 
Range 106-359 100-274 
Total circulatory arrest time (rain) 
Mean -+ SD 27.4 _+ 14 30.1 -+ 13.7 0.34 
Range 11-68 11-60 
Aortic crossclamp time (min) 
Mean + SD 100 _+ 66 74 + 43 0.07 
Range 0-231 0-147 
Table Ill. Intraoperative heparin, protarnine, and activated clotting time for aprotinin-treated and untreated 
(control) patients 
P 
Parameter Aprotinin No apmtinin Value 
Heparin dose (units) 
Mean -- SD 40187 _~ 12653 31771 _+ 8228 0.01 
Range 24,000-79,000 21,000-64,500 
Protamine dose (mg) 
Mean -+ SD 276.5 2 85 332 _+_ 111 0.08 
Range 130-450 150-540 
ACT (sec) 
During CPB (mean _+ SD) 1073 ± 385 681 _+ 231 0.003 
Before total circulatory 1101 _+ 267 770 _+ 173 0.004 
arrest (mean _+ SD) 
had undergone pacemaker insertion. One patient 
in each group underwent resection of a renal 
tumor involving the inferior vena cava under 
hypothermic arrest. One patient in each group 
had a diagnosis of Marfan syndrome. 
Intraoperative parameters. As depicted in Table 
II, aprotinin-treated patients had a longer CPB time 
than untreated patients, perhaps related to the 
greater fraction of patients in this group who had 
undergone previous sternotomy. Aortic crossclamp 
and total circulatory arrest times were similar in 
both groups. The longest CPB time (359 minutes) 
and longest aortic crossclamp time (231 minutes) 
were seen in a 67-year-old man with marfanoid 
features, who had a type A (DeBakey type I) aortic 
dissection 5years after aortic valve replacement and 
required aortic root replacement with reimplanta- 
tion of the coronary arteries. The longest circulatory 
arrest ime (68 minutes) was necessary for a 67-year- 
old woman with an acute type I aortic dissection, 
who underwent repair of the dissection, aortic valve 
resuspension, and quadruple coronary bypass. Both 
of these patients received aprotinin during opera- 
tion. 
Anticoagulation. The aprotinin-treated cohort 
received significantly higher doses of heparin com- 
pared with the untreated group (p = 0.01), but no 
such difference was observed in required protamine 
dosages (Table Ill). A statistically significant pro- 
longation in ACT during CPB (p = 0.003) and 
immediately before circulatory arrest (p = 0.004) 
was achieved in the aprotinin-treated patients com- 
pared with the control group. 
Bleeding parameters. Aprotinin recipients re- 
quired less postoperative transfusion of exogenous 
packed erythrocytes than did control patients (p = 
0.01). The intraoperative blood product require- 
ment and postoperative chest tube output (first 12 
hours) were not markedly different between groups 
(Table IV). Four of 24 aprotinin recipients (16.7%) 
received no exogenous products whatsoever, versus 
one of 24 patients (4.1%) in the control group. 
Eleven patients (45.8%) in the aprotinin group 
received less that 10 units of total blood products, 
compared with only three (12.5%) in the untreated 
cohort. Mean preoperative, postoperative, and dis- 
charge hemoglobin and platelet counts were similar 
among both groups (Table V). 
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Table IV. Comparison of preoperative and postoperative bleeding parameters in aprotinin-treated and 
untreated control patients 
P 
Variable Aprotinin# No aprotinin Value 
Transfusion requirements 
Exogenous packed erythrocytes transfused uring operation 
(units) 
Other products* transfused uring operation (units) 
Exogenous packed erythrocytes transfused after operation 
(units) 
Other products* transfused after operation (units) 
Patients not requiring transfusion 
Patients requiring -<10 total units of exogenous blood products 
Chest tube output (ml) 
First 12 hours 
3.4 -- 0.6 3.5 -+ 0.6 NS 
11.3 _+ 2.6 12.1 _+ 2.1 NS 
1.3 _+ 0.5~ 3.2 +_ 0.8 0.01 
2.2 + 1 6.5 +_ 2.8 NS 
4/24 (16.7%) 1/24 (4.1%) NS 
11/24 (45.8%) 3/24 (12.5%) NS 
488 _+ 92 495 _+ 90 NS 
Results are expressed as mean + standard error. NS, Not significant. 
*Includes platelets, fresh-frozen plasma, and cryoprecipitate. 
Table V. Hematologic parameters among aprotinin- 
treated and untreated (control) patients 
No 
Aprotinin aprotinin 
Hemoglobin (mg/dl) 
Before operation 11.8 _+ 0.3 11.9 _+ 0.5 
POD 3 9.8 _+ 0.3 9.0 +_ 0.2 
Before discharge 10.4 +_ 0.4 9.8 _+ 0.3 
Platelet count (1000 cells/ml) 
Before operation 224 + 15 263 _+ 21 
At arrival at intensive care unit 134 + 14 134 + 15 
Before discharge 380 _+ 29 402 + 45 
Data are mean -+ standard error. 
Adverse events. Complications are summarized 
in Table VI. No anaphylactic reactions were seen 
among patients receiving aprotinin. With regard to 
neurologic omplications, no statistically significant 
difference was noted in the incidence of seizures (p 
not significant), reversible neurologic deficits (p not 
significant), or cerebrovascular ccidents (p not sig- 
nificant) between groups. Similarly, no statistically 
significant difference in the percentage of postoper- 
ative myocardial infarctions (new Q waves) was 
noted (p not significant). Equal fractions of patients 
in each group required temporary postoperative 
dialysis (hemodialysis, continuous arteriovenous 
hemofiltration-dialysis, or continuous venovenous 
hemofiltration-dialysis), and none of the surviving 
patients in either group required permanent hemodi- 
alysis. Renal dysfunction, defined by Sundt and col- 
leagues 1° as a 50% elevation in serum creatinine above 
baseline level, was seen 3.5 times more frequently in 
the aprotinin group, but the difference did not reach 
statistical significance. Patients in either group with 
preoperative r nal insufficiency (serum creatinine l vel 
>1.5 mg/dl) were not more likely to have postopera- 
tive renal dysfunction. No early deaths (within 2 
weeks) were seen in the aprotinin-treated group, 
whereas four early deaths were recorded in the control 
group. The causes of death included left ventricular 
failure and persistent hypotension caused by intraop- 
erative myocardial infarction (one), multisystem organ 
failure (one), ischemic bowel on postoperative day 
(POD) 4 (one), and Pseudomonas septicemia (one). 
Two late deaths (later than 2 weeks but before dis- 
charge) were seen in the aprotinin group. One patient 
died after sudden severe hypoxia caused by intrapul- 
monary hemorrhage on POD 17, and the second 
patient died on POD 20 from fulminant pneumonia 
and septicemia. The latter patient underwent autopsy, 
which confirmed the presence of bronchopneumonia 
with abscess formation. Blood cultures grew multiple 
species. No evidence was found of platelet-fibrin 
thrombi in the heart, kidneys, or other major vascular 
organs. 
Three late deaths in the control group consisted 
of a sudden arrhythmia in one patient (POD 24), 
and progressive irreversible hypoxia in two patients 
(PODs 16 and 41). None of the control patients who 
died underwent postmortem examination. 
Discussion 
Clinical use of aprotinin in patients undergoing 
CPB has been shown to reduce blood loss and blood 
product requirements. 1-4Its safety and efficacy dur- 
ing hypothermic circulatory arrest has been contro- 
versial, however. Aprotinin appears to exert both 
anticoagulant and procoagulant effects. The inhibi- 
tion of protein C, 13 the kallikrein-kinin system, 5 and 
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Table VI. Adverse vents occurring in patients undergoing hypotherrnic circulatory arrest with and without use 
of aprotinin 
Aprotinin No aprotinin 
Adverse event n % n % p* 
Allergic reaction or anaphylaxis 0/24 0 - -  NA NA 
Neurologic events 
Seizures 0/24 0 1/24 4.2 NS 
Reversible neurologic deficit 1/24 4.2 1/24 4.2 NS 
Stroke 3/24 12.5 3/24 12.5 NS 
Myocardial infarction 0/24 0 2/24 8.3 INS 
Renal dysfunction 
Required dialysis 2/24 8.3 2/24 8.3 NS 
Elevation in serum creatinine l vel >50% 7/24 29.2 2/24 8.3 NS 
In-hospital deaths 2/24 8.3 7/24 29.2 NS 
NA, Not applicable; NS, not significant. 
*McNemar's Test (~) for paired data, with continuity correction. 
%-antiplasmin consumption 14translate into a pro- 
thrombotic state, whereas prolongations of the pro- 
thrombin time 15 and the activated partial thrombo- 
plastin time 15' 16 render aprotinin an anticoagulant. To 
predict events under hypothermic onditions, these 
seemingly opposing effects must be combined with the 
effects of hypothermia on fibrinolysis, platelet count 
and function, 17 and clotting factor levels and activity, is 
Because the summation of these effects is not easily 
quantified, the evaluation of the safety of aprotinin 
must be based on the outcome of clinical studies. 
Sundt and associates 1°administered aprotinin to 
20 patients undergoing thoracic aortic procedures 
employing circulatory arrest and deep hypothermia, 
and compared the findings with findings in a well- 
matched retrospective control group. Renal dys- 
function, renal failure necessitating dialysis, and 
death were more frequent in the aprotinin group, 
and autopsies of these patients showed vidence of 
widespread platelet-fibrin thrombi. The adequacy of 
anticoagulation i patients receiving aprotinin has 
been questioned, however. 12 The series was carried 
out before the distorting effects of aprotinin on 
celite ACT were recognized, 16' 19 which may explain 
why the aprotinin group received an average of 
27,850 units of heparin versus 40,250 units in control 
patients, despite identical mean CPB times. 
Westaby and associates 11reported their experi- 
ence with 80 patients undergoing complex aortic 
procedures with and without perioperative aproti- 
nin. They described an increased incidence of 
"bleeding and thrombosis related deaths" in aproti- 
nin recipients. They acknowledged changing their 
heparinization protocol after about 2 years to ac- 
count for aprotinin's effect on celite ACT, but they 
provided no data relating results to time period or 
heparinization protocol. None of the data presented 
were subjected to statistical analysis. Our experience 
provides little support for the findings of Westaby 
and associates. 11 We observed no statistically signif- 
icant difference in the incidence of adverse neuro- 
logic events or myocardial infarctions, and we saw a 
trend toward reduced incidence of in-hospital 
deaths among aprotinin-treated patients. Aprotinin- 
treated patients were benefited by a reduction in the 
requirement for postoperative rythrocytes and 
other blood products and by avoidance of the po- 
tential complications of blood-replacement therapy. 
At our institution, ACT was predominantly mea- 
sured with a kaolin assay, which is essentially unaf- 
fected by aprotinin. 2°' 21 In those cases in which 
celite was used as the activating agent, the ACT was 
maintained at more than 750 seconds. 
We did observe trends in postoperative renal 
dysfunction similar to those reported by Sundt and 
associates. 1° By POD 3, a higher incidence of renal 
dysfunction was encountered in aprotinin recipients. 
This finding did not reach statistical significance. At 
discharge from the hospital, serum creatinine level 
had returned to baseline in five of seven patients 
(71.4%). In both groups, two patients underwent 
temporary continuous arteriovenous or venovenous 
hemodialysis for management of volume overload. 
None of the surviving patients required permanent 
hemodialysis. 
The retrospective design of this study lends itself 
to the introduction of potential bias. The aprotinin 
group and the control group were partially concur- 
1 6 2 0 Goldstein et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1995 
rent. This would appear to introduce the possibility 
of selection bias during the period of overlap, when 
some procedures were being done with aprotinin 
and some without. Aprotinin was first used at this 
institution by one surgeon (C. R. S.), and use was 
restricted to heart-lung transplants, double-lung 
transplants, and procedures in patients who had 
undergone multiple previous heart operations. On 
the basis of results in such patients, the same 
surgeon, who performed 30 of the 48 cases in both 
groups (62.5%), started using aprotinin in all aortic 
dissections. The other three surgeons involved 
adopted use of aprotinin sequentially during the 
overlap period and used the drug uniformly there- 
after. Although the possibility of selection bias can 
never be completely eliminated from a retrospective 
study, in this series treatment assignment by each 
surgeon was not based on patient characteristics. 
Our results suggest hat aprotinin may be safely 
and effectively used in patients undergoing deep 
hypothermia nd circulatory arrest. Findings of 
other authors regarding incidence of adverse vents 
are not substantiated by this study. In view of the 
limited data and the controversial nature of the 
available information, a randomized trial with a 
multicenter design (to ensure adequate number of 
patients and generalizable conclusions) iswarranted 
to investigate the potential advantages (or disadvan- 
tages) of aprotinin use under conditions of hypo- 
thermia and circulatory arrest. 
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Commentary 
Coagulation abnormalities and bleeding commonly oc- 
cur after profoundly hypothermic perfusion and circula- 
tory arrest. This was an obvious area to test the potential 
benefits of aprotinin, and adverse clinical experience was 
reported early, when there was little guidance on intraop- 
erative anticoagulant policy, a' 2 The article from Goldstein 
and colleagues presents a contrary view of the hazards of 
aprotinin in profound hypothermia nd claims benefits. 
The authors confirm an increased incidence of renal 
failure in aprotinin-treated patients but do not report 
multisystem failure from widespread platelet fibrin 
thrombi in the microvasculature. With the exception of 
anaphylaxis, most adverse ffects of aprotinin have been 
attributed to deficiencies in the anticoagulant regimen. In 
reality, improved guidelines emerged only after reports of 
catastrophic events when early protocols were followed) 
The article of Goldstein and colleagues uggests yet 
another modification in anticoagulant policy, with ACT 
maintained at longer than 1000 seconds for patients 
undergoing hypothermic circulatory arrest. 
When aprotinin was found to artifactually prolong 
celite ACT, the setting for inadequate anticoagulation 
became apparent. This situation should have been clearly 
defined before release of the drug in Europe and clinical 
trials in the United States. ACT is also inversely related to 
temperature. Although this effect is expressed equally in 
aprotinin-treated and control patients, it reduces the 
likelihood of reaching an ACT low enough to prompt 
further heparin administration. In the hypothermic pa- 
tients described independently by Westaby and cowork- 
ers ! and Sundt and associates, 2 artifactual prolongation of 
ACT caused aprotinin-treated patients to receive less 
heparin than did control patients. With the benefit of this 
information, Goldstein a d colleagues maintained celite 
ACT at longer than 750 seconds, or longer than 500 
seconds with kaolin provocation, which is unaffected by 
aprotinin. In fact, patients treated with aprotinin received 
considerably more heparin and had ACTs longer than 
1000 seconds, versus around 700 seconds for control 
patients. These are substantial differences between treat- 
ment and historical control patients, and the avoidance of 
disseminated intravascular coagulopathy supports the wis- 
dom of this approach. Another difference between the 
Columbia and Oxford patients was duration of CPB. 
Oxford patients were maintained with a celite ACT longer 
than 700 seconds but had much shorter duration f CPB 
(<100 minutes versus >200 minutes). Differences in the 
ability of platelets to aggregate may" have played a role in 
the Oxford patients with type I dissection who had dis- 
seminated intravascnlar coagulation during circulatory 
arrest. Inhibition by aprotinin of the protein C and 
kallikrein-kinin systems and of % antiplasmin consump- 
tion also predispose the patient oward a prothrombotic 
state during circulatory arrest. 1' 3 
Hypothermia alone causes altered platelet morphology, 
with an increase in mean platelet volume, decreased 
enzyme function, altered arachadonic acid metabolism, 
and platelet sequestration i  the hepatic sinusoids. 4 This 
alteration leads to thrombocytopenia. Decreased ability to 
aggregate arises through reduced thromboxane release 
and the influence of plasmin-related degradation of gly- 
coprotein Ib receptors. In normal circumstances (without 
aprotinin), thorough rewarming reverses impaired aggre- 
gation and depressed enzyme kinetics and is probably the 
single most important factor in the prevention of postop- 
erative bleeding. 5" 6 The influence of hypothermia on the 
clotting cascades is also complex. Hibernating amphibians 
have lower levels of clotting factors in the cold, which 
represents an adaptive response to prevent thrombosis 
during sluggish flow. Primates have lost this facility, apart 
from the kinetic slowing of enzyme activity during cool- 
ing. 7 Consequently, the balance between thrombosis and 
flbrinolysis may be easily disturbed during hypothermic 
low-flow states and circulatory arrest. Cold-induced hy- 
percoagulability may have contributed to widespread mi- 
crovascular coagulopathy in the patients with thoracoab- 
dominal aneurysms in the series of Sundt and coworkers) 
Bacterial trauslocation through ischemic gut can result in 
endotoxin release. 8 This in turn stimulates the monocytes 
to produce thromboplastin and activate the extrinsic 
clotting pathway-. The combination of cold-induced hyper- 
coagulability with endotoxemia results in disseminated 
intravascular coagulation. 
Does the study of Goldstein and colleagues really 
demonstrate benefit from aprotinin treatment? As with 
previous studies, there are methodoiogic weaknesses, 
particularly lack of randomization and the potential for 
bias. The authors admit that a randomized study design 
was not acceptable to the surgeons. This could be 
interpreted as bias in favor of aprotinin. In addition, the 
control group was not concurrent with the study group 
but overlapped it in time. Because the safety of apro- 
tinin had been questioned, was the drug withheld from 
individuals considered to be at high risk for thrombo- 
embolic or nephrotoxic complications? There was no 
difference in intraoperative transfusion requirements 
for erythrocytes, platelets, fresh-frozen plasma, or cryo- 
precipitate. The authors did not state their threshold 
for blood transfusion, but there was no difference in 
chest tube drainage between the groups. Why then did 
patients with aprotinin require f wer blood products in
the postoperative period? 
In summary, this article continues the debate around 
the safety of aprotinin and suggests that prolongation of 
ACT longer than 1000 seconds may prevent he adverse 
effects described by Westaby and coworkers ~and Sundt 
and associates. 2 Benefits from aprotinin in profound 
hypothermia and circulatory arrest are yet to be proved. 
and I agree with the authors that  prospective random- 
ized trial is necessary. Meanwhile, my group uses aproti- 
nin during the rewarming phase after circulatory arrest or 
by topical application or intravenous infusion at the end of 
the procedure if bleeding is a problem. 
Stephen Westaby, MD 
Department of Cardiothoracic Surgery 
Oxford Heart Center 
John Radcliffe Hospital 
Headington, OX3 9DU United Kingdom 
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